A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
- Conditions
- Plaque Psoriasis
- Interventions
- Registration Number
- NCT06108544
- Lead Sponsor
- Takeda
- Brief Summary
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
- Detailed Description
The drug being tested in this study is called TAK-279. TAK-279 is being tested to treat people with moderate to severe plaque psoriasis.
The study will enroll approximately 1000 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups for TAK-279, placebo, or apremilast in a ratio of 2:1:1 which will remain undisclosed to the patient and investigator during the study (unless there is an urgent medical need):
* TAK-279
* Apremilast
* Placebo
This multi-center trial will be conducted worldwide. The overall time to participate in this study is 69 weeks. Participants will go through a screening process to make sure they meet the rules for taking part in the study. This will take up to 35 days. If participants meet the study rules, they will be treated for up to 60 weeks. There will be a safety follow-up visit 4 weeks after their last day of treatment.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1108
- Plaque psoriasis for at least 6 months.
- Moderate to severe disease.
- Candidate for phototherapy or systemic therapy.
- Other forms of psoriasis.
- History of recent infection.
- Prior exposure to TAK-279 or active comparator.
Other protocol defined inclusion/exclusion criteria apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description TAK-279 TAK-279 - Placebo Placebo - Apremilast Apremilast -
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo Baseline, Week 16 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.
Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16 Comparing TAK-279 Against Placebo Baseline, Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving 90% Improvement from Baseline in PASI (PASI-90) at Week 16 Comparing TAK-279 Against Placebo Baseline, Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Placebo Week 16 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. Higher scores indicate worsening. 'Clear' will include all participants who score a 0.
Change from Baseline in the Short Form-36 Health Survey (SF-36) Version 2 Scores at Week 16 Comparing TAK-279 Against Placebo Baseline, Week 16 The SF-36 is a self-administered, validated questionnaire designed to measure generic health-related QoL. This 36-item questionnaire measures 8 domains, including physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health, physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Two summary scores, including the physical component summary (PCS) and mental component summary (MCS), will be calculated ranging from 0 (worst) to 100 (best). Higher scores indicate better QoL.
Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast Baseline to Week 16 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. Higher scores indicate worsening. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.
Percentage of Participants With a Baseline Psoriasis Symptoms and Signs Diary (PSSD) ≥1 who Achieve Weekly Mean Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0 at Week 16 Comparing TAK-279 Against Placebo Week 16 The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease From Baseline at Week 16 Comparing TAK-279 Against Placebo Baseline, Week 16 PGA is a 5-point scale and a score of 0 to 4 should be assigned, based on the category that best describes the severity of active psoriasis of the participant's hands and/or feet (palmoplantar), where 0=clear and 4=severe. Higher scores indicate worsening of severity. It will be evaluated for participants with the presence of active hand or foot psoriasis on Day 1.
Percentage Change from Baseline in BSA Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo Week 16 Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.
Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Placebo Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants Achieving a Scalp-specific Physician's Global Assessment (ssPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo Baseline, Week 16 ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.
Percentage of Participants with a Baseline Dermatology Life Quality Index (DLQI) Score ≥2 who Achieve DLQI Score of 0 or 1 at Week 16 Comparing TAK-279 Against Placebo Week 16 The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).
Change from Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 Among Participants With Nail Involvement at Baseline Comparing TAK-279 Against Placebo Baseline, Week 16 The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each nail will be scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores indicate more severe psoriasis.
Change from Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo Week 16 Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.
Change from Baseline in DLQI at Week 16 Comparing TAK-279 Against Placebo Baseline, Week 16 The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). It will be evaluated for participants with a baseline DLQI score ≥2.
Percentage of Participants With a Baseline PSSD ≥1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Apremilast Week 16 The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.
Change from Baseline in NAPSI Among Participants With Nail Involvement at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each nail will be scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores indicate more severe psoriasis.
Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast Baseline to Week 24 ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.
Change from Baseline in DLQI at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).
Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.
Change from Baseline in the EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Scores at Week 16 Comparing TAK-279 Against Placebo Baseline, Week 16 EQ-5D-5L includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 5 response levels for each domain (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). The scores in the 5 dimensions will be summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health; 0=a health state equivalent to death, and 1=perfect health.
Change in Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) Questionnaire Scores at Week 16 Comparing TAK-279 Against Placebo Week 16 The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score will be expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Percentage of Participants Achieving PASI-75 at Week 16 Comparing TAK-279 Against Apremilast Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants Achieving PASI-90 at Week 16 Comparing TAK-279 Against Apremilast Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants Achieving PASI-75 at Week 24 Comparing TAK-279 Against Apremilast Week 24 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants Achieving PASI-90 at Week 24 Comparing TAK-279 Against Apremilast Week 24 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.
Change from Baseline in Weekly Mean PSSD Symptom Score at Week 16 Comparing TAK-279 Against Apremilast Baseline to Week 16 The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.
Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast Baseline to Week 16 ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.
Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Apremilast Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast Baseline to Week 24 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.
Percentage of Participants Achieving PASI-100 at Week 24 Comparing TAK-279 Against Apremilast Week 24 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Apremilast Week 16 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0.
Percentage of Participants with a Baseline DLQI Score ≥2 who Achieve DLQI Score of 0/1 at Week 16 Comparing TAK-279 Against Apremilast Week 16 The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).
Percent Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.
Percentage of Participants Achieving an sPGA of Clear (0) at Week 24 Comparing TAK-279 Against Apremilast Week 24 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0.
Percentage of Participants With a Baseline DLQI Score ≥2 who Achieve a DLQI Score of 0/1 at Week 24 Comparing TAK-279 Against Apremilast Week 24 The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).
Percentage of Participants With a Baseline PSSD ≥1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 24 Comparing TAK-279 Against Apremilast Week 24 The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.
Change from Baseline in ssPGA at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.
Percentage of Participants Achieving a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease From Baseline at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 PGA is a 5-point scale and a score of 0 to 4 should be assigned, based on the category that best describes the severity of active psoriasis of the participant's hands and/or feet (palmoplantar), where 0=clear and 4=severe. Higher scores indicate worsening of severity. It will be evaluated for participants with the presence of active hand or foot psoriasis on Day 1.
Change from Baseline in SF-36 Version 2 Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 The SF-36 is a self-administered, validated questionnaire designed to measure generic health-related QoL. This 36-item questionnaire measures 8 domains, including physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health, physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Two summary scores, including the PCS and MCS, will be calculated ranging from 0 (worst) to 100 (best). Higher scores indicate better QoL.
Change from Baseline in the EQ-5D-5L Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 EQ-5D-5L includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 5 response levels for each domain (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). The scores in the 5 dimensions will be summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health; 0=a health state equivalent to death, and 1=perfect health.
Change from Baseline in the WPAI-PSO Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast Baseline, Weeks 16 and 24 The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score will be expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Weeks 24 and 40 Comparing TAK-279 Against Apremilast Baseline, Weeks 24 and 40 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.
Percentage of Participants Achieving PASI-75 at Weeks 24 and 40 Comparing TAK-279 Against Apremilast Weeks 24 and 40 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants Achieving PASI-90 at Weeks 24 and 40 Comparing TAK-279 Against Apremilast Weeks 24 and 40 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.
Time to Relapse for PASI-75 Responders at Week 40 Comparing TAK-279 Against Placebo Up to Week 60 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants With Maintenance of PASI-75 Response at Week 60 Comparing TAK-279 Against Placebo Week 60 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.
Percentage of Participants with Maintenance of sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 60 Comparing TAK-279 Against Placebo Baseline to Week 60 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.
Percentage of Participants With a Disease Relapse Comparing TAK-279 Against Placebo Week 40 Relapse is defined as a percent change from baseline in PASI score that is at least 50% worse than that observed at Week 40. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Higher scores indicate worsening.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESI) Up to week 69 TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product. An AESI (serious or nonserious) is an adverse event of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator may be appropriate.
Number of Participants With Clinically Significant Abnormalities in Vital Signs Up to week 69 Number of Participants With Clinically Significant Laboratory Values Up to week 69 Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings Up to week 69
Trial Locations
- Locations (217)
Advanced Medical Research, PC
🇺🇸Atlanta, Georgia, United States
Skinsense Medical Research - 411 2nd Ave N - Probity - PPDS
🇨🇦Saskatoon, Saskatchewan, Canada
ETG Siedlce - PPDS
🇵🇱Siedlce, Mazowieckie, Poland
FutureMeds - Targowek - PPDS
🇵🇱Warszawa, Mazowieckie, Poland
NZOZ Osteo Medic SC Artur Racewicz Jerzy Supronik
🇵🇱Bialystok, Podlaskie, Poland
Florida Academic Centers Research
🇺🇸Miami, Florida, United States
First OC Dermatology Research Inc.
🇺🇸Fountain Valley, California, United States
Allcutis Research LLC
🇺🇸Beverly, Massachusetts, United States
Divine Dermatology and Aesthetics, LLC
🇺🇸Atlanta, Georgia, United States
DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location
🇺🇸Clarksville, Indiana, United States
Cahaba Dermatology Skin Health Center
🇺🇸Hoover, Alabama, United States
FXM Research Miramar
🇺🇸Miramar, Florida, United States
San Marcus Research Clinic Inc
🇺🇸Miami Lakes, Florida, United States
Beacon Clinical Research LLC
🇺🇸Brockton, Massachusetts, United States
Center For Clinical Studies, LTD. LLP - 451 N Texas Ave
🇺🇸Webster, Texas, United States
Wright State Physicians
🇺🇸Fairborn, Ohio, United States
Psoriasis Treatment Center of Central New Jersey
🇺🇸East Windsor, New Jersey, United States
Mount Sinai Doctors -234 E 85th St
🇺🇸New York, New York, United States
Zenith Research, Inc.
🇺🇸Beverly Hills, California, United States
Dermatology & Advanced Aesthetics
🇺🇸Lake Charles, Louisiana, United States
Dermatology Institute and Skin Care Center
🇺🇸Santa Monica, California, United States
Centro de Investigaciones Médicas Tucumán - PPDS
🇦🇷San Miguel de Tucumán, Argentina
NorthShore Medical Group Dermatology - Skokie
🇺🇸Skokie, Illinois, United States
Houston Center for Clinical Research, LLC
🇺🇸Sugar Land, Texas, United States
Austin Institute for Clinical Research, Inc. - Pflugerville - ClinEdge - PPDS
🇺🇸Pflugerville, Texas, United States
Lenus Research & Medical Group
🇺🇸Sweetwater, Florida, United States
Lawrence J Green, MD LLC
🇺🇸Rockville, Maryland, United States
Oakland Hills Dermatology - 3400 Auburn Rd
🇺🇸Auburn Hills, Michigan, United States
Revival Research Corporation - Florida - ClinEdge - PPDS
🇺🇸Doral, Florida, United States
Toronto Research Centre - Probity - PPDS
🇨🇦Toronto, Ontario, Canada
Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity - PPDS
🇨🇦Hamilton, Ontario, Canada
Diagnostic Consultative Center XXVIII - Sofia - EOOD
🇧🇬Sofia, Sofia-Grad, Bulgaria
ClinOhio Research Services
🇺🇸Columbus, Ohio, United States
Ambulatory for Specialized Medical Care- Group Practice in Dermatology - Clinic EuroDerma OOD
🇧🇬Sofia, Sofia-Grad, Bulgaria
Virginia Clinical Research - 6160 Kempsville Cir
🇺🇸Norfolk, Virginia, United States
Conexa Investigación Clínica S.A.
🇦🇷Ciudad Autónoma de Buenos Aires, Argentina
Center For Clinical Studies,LTD. LLP - 451 N Texas Ave
🇺🇸Webster, Texas, United States
Centro de Investigacion Clínica - CEDIC
🇦🇷Ciudad Autónomade Buenos Aires, Argentina
Diagnostic Consultative Centre - Focus-5 - LZIP EOOD
🇧🇬Sofia, Sofia-Grad, Bulgaria
Dermatology Research Institute, Inc. - Probity - PPDS
🇨🇦Calgary, Alberta, Canada
Wiseman Dermatology Research Inc. - Probity - PPDS
🇨🇦Winnipeg, Manitoba, Canada
Siena Medical Research
🇨🇦Westmount, Quebec, Canada
Sir Run Run Shaw Hospital Zhejiang University School of Medicine - Qingchun Campus
🇨🇳Hangzhou, Zhejiang, China
DermEdge Research - Probity - PPDS
🇨🇦Mississauga, Ontario, Canada
CLINTRIAL s.r.o.
🇨🇿Praha, Praha, Hlavní Mesto, Czechia
Pratia Brno s.r.o. - PRATIA - PPDS
🇨🇿Brno, Jihomoravský Kraj, Czechia
Hospital Of Skin And Venereal Diseases of Thessaloniki
🇬🇷Thessaloniki, Greece
Henan Provincial People's Hospital
🇨🇳Zhengzhou, Henan, China
The Second Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Dermatrials Research
🇨🇦Hamilton, Ontario, Canada
XLR8 Medical Research - Probity - PPDS
🇨🇦Windsor, Ontario, Canada
SKiN Centre for Dermatology - Peterborough - Probity - PPDS
🇨🇦Peterborough, Ontario, Canada
Klinische Forschung Dresden GmbH (KFGN) - PRATIA - PPDS
🇩🇪Dresden, Sachsen, Germany
Dermskin s.r.o.
🇨🇿Olomouc, Olomoucký Kraj, Czechia
CaRe Clinic-Red Deer
🇨🇦Red Deer, Alberta, Canada
Affiliated Hospital of Jiangsu University
🇨🇳Zhenjiang, Jiangsu, China
Lynderm Research Inc - Probity - PPDS
🇨🇦Markham, Ontario, Canada
West China Hospital Sichuan University
🇨🇳Chengdu, Sichuan, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, Guangdong, China
Oshawa Clinic-117 King St
🇨🇦Oshawa, Ontario, Canada
CCR Ostrava s.r.o.
🇨🇿Ostrava, Moravskoslezský Kraj, Czechia
AP-HM- Hôpital de La Timone
🇫🇷Marseille, France
Hôpital Charles Nicolle-1 Rue de Germont
🇫🇷Rouen, France
Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS
🇨🇿Praha 1, Czechia
Pratia Pardubice a.s. - PRATIA - PPDS
🇨🇿Pardubice, Czechia
Nemocnice AGEL Novy Jicin a.s
🇨🇿Novy Jicin, Moravskoslezský Kraj, Czechia
Centre Hospitalier Le Mans
🇫🇷Le Mans cedex 9, Ohio, France
Medizinisches Versorgungszentrum DermaKiel GmbH
🇩🇪Kiel, Germany
Szegedi Tudomanyegyetem
🇭🇺Szeged, Csongrád, Hungary
Huashan Hospital Fudan University - PPDS
🇨🇳Shanghai, China
HaEmek Medical Center
🇮🇱Afula, Israel
Fachklinik Bad Bentheim
🇩🇪Bad Bentheim, Niedersachsen, Germany
Praglandia s.r.o.
🇨🇿Praha 5, Ohio, Czechia
Hadassah Medical Center- Ein Kerem - PPDS
🇮🇱Jerusalem, Yerushalayim, Israel
Rabin Medical Center - PPDS
🇮🇱Petach Tikva, Israel
Dermamedica, s.r.o. - Kozni Ambulance Nachod
🇨🇿Nachod, Královéhradecký Kraj, Czechia
Health Center 4, Center of Diagnostics
🇱🇻Riga, Latvia
Health Center 4, Clinic of Dermatology
🇱🇻Riga, Latvia
Tel Aviv Sourasky Medical Center Ichilov - PPDS 27004
🇮🇱Tel Aviv-Yafo, Tel-Aviv, Israel
Riga 1st Hospital
🇱🇻Riga, Latvia
J. Kisis
🇱🇻Riga, Latvia
Pro Familia Altera Sp. z o.o.
🇵🇱Katowice, Slaskie, Poland
Somogy Varmegyei Kaposi Mor Oktato Korhaz
🇭🇺Kaposvár, Somogy, Hungary
Veseliba un estetika
🇱🇻Riga, Latvia
WroMedica
🇵🇱Wroclaw, Dolnoslaskie, Poland
Clinical Research Group Sp. z o.o
🇵🇱Warszawa, Mazowieckie, Poland
Centrum Badan Klinicznych PI-House sp. z o.o.
🇵🇱Gdansk, Pomorskie, Poland
St Luke's Hospital
🇬🇧Bradford, West Yorkshire, United Kingdom
Hospital Universitario Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Velocity Clinical Research, High Wycombe - PPDS
🇬🇧High Wycombe, Buckinghamshire, United Kingdom
Twoja Przychodnia PCM
🇵🇱Poznań, Wielkopolskie, Poland
Royalderm
🇵🇱Warszawa, Poland
GCM Medical Group, PSC -62 Calle Jose Marti
🇵🇷San Juan, Puerto Rico
Hospital de La Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Globe Badania Kliniczne Spólka z o.o. - Klodzko
🇵🇱Klodzko Dolnoslaskie, Poland
ETG Lublin - PPDS
🇵🇱Lublin, Poland
TCR Medical Corporation
🇺🇸San Diego, California, United States
Vivida Dermatology - Flamingo Rd - Probity - PPDS
🇺🇸Las Vegas, Nevada, United States
Hospital A.Syggros
🇬🇷Athens, Attiki, Greece
Duke Dermatology Clinic
🇺🇸Durham, North Carolina, United States
Texas Dermatology and Laser Specialists
🇺🇸San Antonio, Texas, United States
Dermatology Clinical Research Center of San Antonio
🇺🇸San Antonio, Texas, United States
4 Medical Clinical Solutions (4MCS) Swinton - PPDS
🇬🇧Ilford, Essex, United Kingdom
China-Japan Friendship Hospital
🇨🇳Beijing, Beijing, China
The Third Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
Medical Dermatology Specialists
🇺🇸Phoenix, Arizona, United States
Oregon Medical Research Center PC
🇺🇸Portland, Oregon, United States
Centre For Dermatology and Cosmetic Surgery - Probity - PPDS
🇨🇦Richmond Hill, Ontario, Canada
Skin Specialists PC
🇺🇸Omaha, Nebraska, United States
Advanced Clinical Research Institute (ACRI) - Florida
🇺🇸Tampa, Florida, United States
Olympian Clinical Research - 6331 Memorial Hwy
🇺🇸Tampa, Florida, United States
Total Dermatology
🇺🇸Birmingham, Alabama, United States
Noble Clinical Research
🇺🇸Tucson, Arizona, United States
Johnson Dermatology Clinic
🇺🇸Fort Smith, Arkansas, United States
Burke Pharmaceutical Research
🇺🇸Hot Springs, Arkansas, United States
UNISON Clinical Trials (Shahram Jacobs md inc.)
🇺🇸Encino, California, United States
Metropolis Dermatology Downtown LA - Probity - PPDS
🇺🇸Los Angeles, California, United States
Northridge Clinical Trials
🇺🇸Northridge, California, United States
Long Beach Research Institute, LLC
🇺🇸Long Beach, California, United States
University Clinical Trials
🇺🇸San Diego, California, United States
DS Research of Kentucky
🇺🇸Louisville, Kentucky, United States
Skin Care Physicians of Georgia
🇺🇸Macon, Georgia, United States
Minnesota Clinical Study Center
🇺🇸Fridley, Minnesota, United States
ALLCUTIS Research, LLC.
🇺🇸Portsmouth, New Hampshire, United States
Sadick Research Group
🇺🇸New York, New York, United States
Derm Research Center of NY
🇺🇸Stony Brook, New York, United States
University of Pittsburgh Medical Center-3601 5th Ave
🇺🇸Pittsburgh, Pennsylvania, United States
Apex Clinical Research Center
🇺🇸Mayfield Heights, Ohio, United States
Cumberland Skin Center for Clinical Research - Objective Health - PPDS
🇺🇸Hermitage, Tennessee, United States
Tennessee Clinical Research Center
🇺🇸Nashville, Tennessee, United States
Modern Research Associates
🇺🇸Dallas, Texas, United States
UT Physicians Dermatology - Bellaire Station
🇺🇸Bellaire, Texas, United States
Arlington Research Center
🇺🇸Arlington, Texas, United States
North Texas Center for Clinical Research
🇺🇸Frisco, Texas, United States
Instituto de Neumonologia y Dermatologia
🇦🇷Ciudad Autónoma de Buenos Aires, Argentina
STAT Research S.A.
🇦🇷Ciudad Autónoma de Buenos Aires, Argentina
Medical Center Unimed EOOD
🇧🇬Sevlievo, Gabrovo, Bulgaria
Diagnostic and Consulting Center Aleksandrovska EOOD
🇧🇬Sofia, Sofia-Grad, Bulgaria
Medical Center Hera EOOD
🇧🇬Sofia, Sofia-Grad, Bulgaria
Medical Center Medconsult Pleven OOD
🇧🇬Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment -Dr. Georgi Stranski -Gen. V. Vazov Str 91
🇧🇬Pleven, Bulgaria
Diagnostic Consultative Center Sveti Georgi EOOD
🇧🇬Haskovo, Bulgaria
The Centre for Clinical Trials Inc. - Probity - PPDS
🇨🇦Oakville, Ontario, Canada
DermEffects - Probity - PPDS
🇨🇦London, Ontario, Canada
Dr. S. K. Siddha Medicine Professional Corporation - Probity - PPDS
🇨🇦Richmond Hill, Ontario, Canada
Alliance Clinical Trials - Probity - PPDS
🇨🇦Waterloo, Ontario, Canada
Canadian Dermatology Centre - Probity - PPDS
🇨🇦Toronto, Ontario, Canada
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The First Affiliated Hospital With Nanjing Medical University(Jiangsu Province Hospital)
🇨🇳Nanjing, Jiangsu, China
The Second Affiliated Hospital of Kunming Medical University
🇨🇳Kunming, Yunnan, China
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha 10, Czechia
SRH Wald-Klinikum Gera GmbH
🇩🇪Gera, Thüringen, Germany
Praxis fur Dermatologie and Venerologie
🇩🇪Dresden, Sachsen, Germany
FutureMeds - Berlin - PPDS
🇩🇪Berlin, Germany
Dermatologikum Hamburg
🇩🇪Hamburg, Germany
University General Hospital ''ATTIKON''
🇬🇷Chaidari, Attiki, Greece
University Hospital of Ioannina
🇬🇷Loannina, Greece
Allergo-Derm Bakos Kft- Szolnok-Baross utca 20
🇭🇺Szolnok, Jász-Nagykun-Szolnok, Hungary
Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus
🇭🇺Debrecen, Hajdú-Bihar, Hungary
Papageorgiou General Hospital of Thessaloniki
🇬🇷Thessaloniki, Greece
Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz
🇭🇺Szombathely, Vas, Hungary
The Chaim Sheba Medical Center - PPDS
🇮🇱Ramat Gan, Tel-Aviv, Israel
Semigallia
🇱🇻Kuldīga, Latvia
ClinMedica Research
🇵🇱Skierniewice, Lódzkie, Poland
Adoria
🇱🇻Riga, Ohio, Latvia
Smite Aija doctor practice in dermatology, venerology
🇱🇻Talsi, Talsu Aprinkis, Latvia
Centrum Medyczne ALL-MED
🇵🇱Krakow, Malopolskie, Poland
Krakowskie Centrum Medyczne - FutureMeds - PPDS
🇵🇱Kraków, Malopolskie, Poland
RCMed Oddzial Sochaczew
🇵🇱Sochaczew, Mazowieckie, Poland
Centrum Medyczne Chojnice - PRATIA - PPDS
🇵🇱Chojnice, Pomorskie, Poland
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Katowicach
🇵🇱Katowice, Slaskie, Poland
Solumed Centrum Medyczne
🇵🇱Poznan, Wielkopolskie, Poland
Dermedic Jacek Zdybski
🇵🇱Ostrowiec Swietokrzyski, Swietokrzyskie, Poland
Diamond Clinic
🇵🇱Krakow, Poland
MCM Krakow - PRATIA - PPDS
🇵🇱Kraków, Poland
Hospital de Manises
🇪🇸Manises, Valencia, Spain
Hospital Universitario de Gran Canaria Doctor Negrin
🇪🇸las Palmas de Gran Canaria, Spain
Hospital Universitario La Paz - PPDS
🇪🇸Madrid, Spain
Accellacare - North London Clinical Studies Centre
🇬🇧Northwood, Middlesex, United Kingdom
Whipps Cross Hospital
🇬🇧London, London, City Of, United Kingdom
Salford Royal Hospital - PPDS
🇬🇧Salford, Lancashire, United Kingdom
Accellacare of Northamptonshire
🇬🇧Harrow, Middlesex, United Kingdom
Velocity Clinical Research, North London - PPDS
🇬🇧London, Middlesex, United Kingdom
David Fivenson MD Dermatology PLLC
🇺🇸Ann Arbor, Michigan, United States
University of Michigan Hospital - 1500 E Medical Center Dr
🇺🇸Ann Arbor, Michigan, United States
The Skin Surgery Center for Clinical Research - Objective Health - PPDS
🇺🇸Winston-Salem, North Carolina, United States
Skin Sciences, PLLC
🇺🇸Louisville, Kentucky, United States
Wake Forest Baptist Health Department of Dermatology - 4618 Country Club Rd
🇺🇸Winston-Salem, North Carolina, United States
Medical Center Asklepii OOD
🇧🇬Dupnitsa, Kjustendil, Bulgaria
Medical Center Exacta Medica - Vasil Levski 60
🇧🇬Pleven, Bulgaria
Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
🇧🇬Sofia, Sofia-Grad, Bulgaria
Multiprofile Hospital for Active Treatment - Dobrich AD
🇧🇬Dobrich, Bulgaria
Ostrowieckie Centrum Medyczne
🇵🇱Ostrowiec Swietokrzyski, Swietokrzyskie, Poland
Ambulatorium Barbara Bazela
🇵🇱Elblag, Poland
DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski, s.c.
🇵🇱Osielsko, Poland
MBAL Skin Systems, Doganovo
🇧🇬Elin Pelin, Sofia, Bulgaria
Multiprofile Hospital For Active Treatment Dr Tota Venkova
🇧🇬Gabrovo, Bulgaria
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie
🇵🇱Warszawa, Mazowieckie, Poland
MICS Centrum Medyczne Torun - MICS - PPDS
🇵🇱Torun, Ohio, Poland
Centrum Medyczne Angelius Provita
🇵🇱Katowice, Slaskie, Poland
MC Comac Medical - IRN - PPDS
🇧🇬Sofia, Sofia-Grad, Bulgaria
Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska
🇵🇱Lublin, Lubelskie, Poland
Accellacare of Yorkshire
🇬🇧Chorley, Lancashire, United Kingdom
Brunswick Dermatology Centre - Probity - PPDS
🇨🇦Fredericton, New Brunswick, Canada
Pécsi Tudomanyegyetem - Vasvari Pal u.
🇭🇺Pecs, Hungary
Twoja Przychodnia Nowosolskie Centrum Medyczne sp. z o.o
🇵🇱Nowa Sol, Lubuskie, Poland
Centrum Terapii Wspolczesnej
🇵🇱Lódz, Lódzkie, Poland
ETG Warszawa - PPDS
🇵🇱Warszawa, Mazowieckie, Poland
Centrum Uslug Medycznych MaxMed
🇵🇱Bochnia, Poland
ETYKA Osrodek Badan Klinicznych
🇵🇱Olsztyn, Poland
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdyni
🇵🇱Gdynia, Pomorskie, Poland
dermMEDICA Sp. z o.o
🇵🇱Wrocław, Poland
Montefiore Dermatology - BRANY - PPDS
🇺🇸Bronx, New York, United States
Alberta DermaSurgery Centre - Probity - PPDS
🇨🇦Edmonton, Alberta, Canada
VIDA Dermatology - Probity - PPDS
🇨🇦Edmonton, Alberta, Canada
First Hospital of Shanxi Medical University
🇨🇳Taiyuan, Shanxi, China